Active Disease Treatment
Transforming the Treatment of Inflammatory Diseases
We envision a future where inflammatory diseases are treated by actively guiding the immune system toward resolution rather than chronic suppression. At EVolution Therapeutics, we are building a next-generation RNA therapeutics platform that combines precision nanoparticle delivery with immunologically informed design to reprogram inflammatory pathways at their source.
By integrating immune modulation, regenerative biology, and advanced RNA delivery technologies, our approach is designed to restore tissue homeostasis, accelerate repair, and support long-term health. We aim to harness the body’s innate capacity for healing — unlocking new possibilities in regenerative medicine, chronic disease intervention, and healthy longevity.
Loaded Nanoparticles as a Treatment for Chronic Inflammation
Lipid nanoparticles (LNPs) are nano-sized, lipid-based structures capable of encapsulating bio-active molecules such as proteins, lipids, and nucleic acids. They can be engineered as precision delivery systems to transport therapeutic cargo in a controlled and targeted way within the body, influencing cellular behaviour and modulating biological pathways involved in both normal physiology and disease.
Regulation of inflammation is central to this approach. Persistent or dysregulated inflammation underpins many serious conditions, including cancer, cardiovascular disease, and chronic inflammatory disorders. By delivering specific bio-active signals directly to affected tissues, nanoparticle technologies can be used to shape how the innate immune system responds within damaged or diseased environments.
Our research has identified specific molecular cargo that influences immune system behaviour and plays a critical role in the control of inflammation. We are delivering this cargo using a targeted nanoparticle approach embedded within a biodegradable delivery system, designed to localise activity at the site of disease and support the transition from inflammation toward resolution and repair.
A New Approach to Treating Inflammatory Disease at Its Source
Inflammatory diseases can become trapped in the ‘inflammatory phase’ — a stage where the innate immune system should transition from defence to repair but fails to do so. This results in persistent inflammation, ongoing tissue damage, and an inability to restore normal function.
Our nanoparticle therapy is designed to intervene at this critical point by delivering targeted inflammation-modifying cargo that helps shift immune cells away from a pro-inflammatory state and toward pro-resolving behaviour, enabling the healing process to restart.
Our research is focused on developing a new generation of immune-modulating therapeutics. By combining expertise in immunology with precision nanoparticle delivery, we aim to translate this science into targeted treatments that restore immune balance and promote resolution in complex inflammatory diseases.
Diabetic Foot Ulcers (DFU)
People affected worldwide
$ Cost of treatment for an advanced stage wound
%
3-to-5 year reoccurence rate
%
Patients will require an amputation
A never ending problem…
The non-healing wound challenges
Economic burden
At an annual cost of £5.6 billion, non-healing wounds cost the same as managing obesity.
Human resource intensive
70% of NHS wound care cost is associated with community healthcare visits, emphasising the lack of a viable wound care therapy
Low patient quality of life
Overall patient quality of life of individuals with a non-healing wound is extremely poor
Environmental impacts
A current reliance on non-biodegradable wound dressings
Our Vision to Transform
At EVolution Therapeutics, we’re pioneering a transformative approach to inflammatory disease treatment using nanoparticle-based therapeutics. Our research focuses on immunology-driven bio-active molecules and how they can be delivered using precision nanoparticle systems for therapeutic effect. Through open innovation and collaboration, we aim to redefine disease management by developing targeted treatments that actively modulate inflammation and address significant unmet medical needs.
Learn about Us…
Read about our Journey
Our Team
Meet our Experts
EVolution Therapeutics is a preclinical-stage biotechnology company spun out of Aston University. Nanoparticle-based therapeutics represent a next generation of treatment for intractable diseases, and we are pioneering the development of this platform to modulate the innate immune response in inflammatory conditions. At EVolution Therapeutics, we have assembled a multidisciplinary team with deep expertise in immunology, nanoparticle science, and translational research, united by a shared focus on advancing innovative therapies from discovery toward clinical impact.
Dr. Sri Bellary
Clinical Consultant
Dr. Matt Vassey
Chief Operating Officer
Dr. James Gavin
Co-Founder & CEO
Prof. Andrew Devitt
Co-Founder & CTO
Dr. Ivana Milic
Co-Founder & CSO
Liz Dainty
Chief Financial Officer
Latest News & Events
Hear from the Team
